BeijingMay 25, 2026 /PRNewswire/ — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereinafter referred to as “Biocytogen”, SSE: 688796; HKEX: 02315) today announced the official launch of RenSuper Workstation, a new generation AI-driven antibody discovery platform. It provides global partners with a large-scale, experimentally validated, off-the-shelf library of fully human therapeutic antibodies, supporting a shift in antibody discovery from “customized projects” to a “searchable, scalable, and more efficient” new model.
Foundation of the Platform: Real Fully Human Antibody Library + AI and Automation Dual Engines
The core foundation of RenSuper Workstation comes from Biocytogen’s long-term accumulation of large-scale immunization and real-world data systems, built upon its proprietary RenMice® fully human antibody mouse platform.
Targeting over 1,000 potentially druggable targets, Biocytogen conducts large-scale in vivo immunization and screening, constructing a vast “off-the-shelf molecule library” of real fully human antibody sequences. Unlike virtual libraries generated by predictive models, each sequence in this “real library” originates from in vivo immunization and has been experimentally validated, possessing real binding and functional evidence, providing more reliable source molecular assets for antibody research and development.
On this basis, RenSuper integrates large-scale in vivo immunization, next-generation sequencing (NGS), AI-driven high-throughput screening, and experimental validation into a unified workflow. Combined with a high-throughput automated experimental system, it achieves a rapid closed loop from target to lead molecule, significantly improving screening efficiency and R&D certainty.
Platform Capability Highlights: Making “Off-the-Shelf Molecules” Truly Usable, Developable, and Iterable
RenSuper Workstation is designed for diverse innovative antibody drug formats, supporting the discovery and development of monoclonal antibodies (mAbs), bispecific/multispecific antibodies (bsAbs/msAbs), antibody-drug conjugates (ADCs), VHHs, fully human TCRs, and other therapeutic modalities. It offers significant advantages in “usability” and “engineering feasibility.”
Truly Usable Off-the-Shelf Antibody Molecule Library: From “Searchable” to “Developable”
Unlike sequence collections reliant on computational predictions, the antibody sequences in the RenSuper library have all undergone binding validation, affinity determination, specificity assessment, and key functional experimental validation, directly supporting subsequent development decisions.
Furthermore, molecules in the library possess a good foundation for developability, such as the absence of unexpected glycosylation sites or free cysteines, reducing risks in downstream engineering optimization and CMC development, making “off-the-shelf” molecules truly valuable for translation.
Intelligent Search and Multi-Dimensional Screening: Transforming Antibody Discovery into a “One-Click Access” Process
The core concept of RenSuper Workstation is to transform antibody discovery from traditional project-based R&D into an intelligent process that is searchable, screenable, and rapidly iterable.
Users can perform combined searches within the platform based on multiple dimensions such as target type, epitope characteristics, functional requirements, and physicochemical properties, quickly locating candidate molecules that meet their needs. Subscribers can export sequences and metadata with one click, providing an efficient entry point for constructing complex formats like bispecific or trispecific antibodies.
Welcome to visit RenSuper Workstation: https://www.rensuperbio.com/
AI-Empowered Candidate Screening: Rapidly Identifying High-Quality Leads from Massive Data
Based on large-scale real data, RenSuper has built an AI-driven candidate molecule optimization system, supporting multi-dimensional analysis and ranking from structure prediction and epitope inference to functional trend assessment. This helps R&D teams quickly identify high-quality candidate molecules with drug potential, reducing blind trial-and-error in early screening.
More importantly, Biocytogen’s established AI screening system has been validated on multiple challenging, clinically proven targets. Taking the RenNano fully human heavy-chain-only antibody (HCAb) platform as an example, in a screening system using SPR affinity assessment as the standard, the platform’s average positive hit rate reached 46%, with a maximum hit rate of up to 98%, demonstrating powerful antibody discovery capabilities for challenging targets such as those with complex structures.
Meanwhile, supported by the AI+NGS-driven quality control system, the success rate for achieving high purity (≥90%) in FC format antibody expression in 2026 reached 82%, further demonstrating the significant improvement in candidate molecule developability and subsequent translation efficiency brought by AI screening. These data validate the effectiveness of Biocytogen’s “data + intelligence + experimental validation” closed-loop model, indicating that the system can continuously provide global partners with faster, more accurate, and more certain target-to-lead antibody discovery solutions.
From Screening to Validation to Development: Closed-Loop Acceleration via High-Throughput Automation
RenSuper Workstation is not limited to the “intelligent screening” level; it deeply integrates backend high-throughput automation capabilities, forming a scalable discovery and development closed loop.
Currently, the RenSuper High-Throughput Antibody Intelligent Manufacturing Center has established an automated platform covering the entire lifecycle of antibody protein production. It achieves standardization and continuous operation in key steps such as bacterial inoculation, plasmid extraction, transfection, fed-batch culture, and purification, stably supporting large-scale antibody sample preparation and rapid validation needs.
Relying on this automated intelligent manufacturing system, antibody protein output capacity is stable at an average of 50–100 mg, with a throughput of up to 800 samples/day and 5,000 samples/week. This industrial-scale production capacity not only efficiently handles the rapid validation of results from front-end AI screening but also significantly accelerates the overall progression of candidate antibodies from molecular design, expression, and purification to functional evaluation, providing a stable, efficient, and scalable manufacturing foundation for high-throughput antibody development.
Antibody Discovery Enters a New Era of “Efficiency, Certainty, and Intelligent Driving”
Dr. Yuelei Shen, Founder and CEO of Biocytogen, stated: “We believe the future of antibody discovery will be dominated by efficiency, certainty, and data-driven intelligent capabilities. RenSuper’s goal is to make antibody discovery searchable, scalable, and more efficient, significantly reducing the time cost and complexity of the early discovery phase, accelerating the development of innovative therapies, and bringing new drugs to patients faster.”
The launch of RenSuper Workstation is not only a comprehensive upgrade of Biocytogen’s own technology system but also provides a scalable “target-to-lead” solution for antibody discovery. Through the triple-driven architecture of “real library + AI + automation,” antibody discovery is moving from lengthy trial-and-error towards a high-efficiency, low-risk intelligent era.
This launch further strengthens Biocytogen’s strategic vision of becoming the “global birthplace of new drugs,” continuously empowering global drug R&D partners with a faster and more efficient biopharmaceutical innovation system.
About Biocytogen
Biocytogen (Stock Codes: 688796.SH; 02315.HK) is an international biotechnology company driven by innovative technology for new drug R&D, committed to becoming the global birthplace of new drugs. Centered on its proprietary gene editing technology, the company has built a dual-engine platform of “fully human antibody molecule library + target humanized mouse library,” systematically accelerating global drug R&D. Biocytogen independently developed the RenMice® fully human antibody platform (including RenMab®, RenLite®, RenNano®, RenTCR™, RenTCR mimic™) for the discovery of therapeutic fully human monoclonal antibodies, bispecific/multispecific antibodies, bispecific ADCs, nanobodies, and TCR-like antibodies. Targeting over 1,000 potentially druggable targets, the company is advancing a large-scale antibody discovery program – “One Thousand Mice, Ten Thousand Antibodies™” – having built a library of over 1 million real fully human antibody sequences and opening up global collaborations. As of December 31, 2025, Biocytogen had signed over 350 drug co-development/licensing/transfer agreements. The company’s sub-brand, BioMice, has established thousands of genetically engineered animal/cell models, possesses the world’s largest collection of target humanized mouse models, and provides global clients with full-chain support including preclinical pharmacology and efficacy studies, gene editing services, and model construction. Biocytogen is headquartered in Beijing, with branches in China (Haimen, Jiangsu; Shanghai), the United States (Boston, San Francisco, San Diego), and Heidelberg, Germany, forming a global R&D and operational network. For more information, please visit the official website: https://biocytogen.com.cn/
Biocytogen Contact Information